Australia and Indonesia Join WHO WLA Network, Creating New Opportunities for Chinese Pharmaceutical Companies
Currently, Chinese pharmaceutical companies face challenges such as international market access barriers and technical standard disparities during their global expansion. As China has not yet been formally included in the WLA catalog, exported drugs still require rigorous review by target markets.
However, the expansion of the WLA network also brings significant opportunities for Chinese pharmaceutical companieshttps://www.jxserum.com/:
If China successfully joins the WLA in the future, it will help companies more smoothly enter international procurement systems and shorten product export cycles.
It will encourage companies to adopt international high standards, strengthen R&D investment and quality management, and enhance core competitiveness.
It will facilitate pharmaceutical trade and industrial collaboration under international cooperation initiatives such as the Belt and Road.
In November 2025, China's National Medical Products Administration (NMPA) met with WHO officials, expressing active progress in vaccine WLA evaluation and commitment to continuously enhancing drug regulatory capabilities to ensure public medication safety.
In the future, as more countries join the WLA network, the resilience of the global pharmaceutical supply chainhttps://www.jxserum.com/hot-product-list/ is expected to strengthen further, promoting fairer and more accessible medicines worldwide.
Chinese pharmaceutical companies should seize this trend, actively promote international transformation, strengthen compliance systems, and prepare for integration into the global pharmaceutical value chain.